These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

763 related items for PubMed ID: 30553527

  • 1. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y, Bewersdorf JP, Stahl M, Zeidan AM.
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
    Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, Daver N.
    Adv Exp Med Biol; 2018 Mar; 995():97-116. PubMed ID: 30539507
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
    Liu Y, Wang S, Schubert ML, Lauk A, Yao H, Blank MF, Cui C, Janssen M, Schmidt C, Göllner S, Kleist C, Zhou F, Rahfeld JU, Sauer T, Schmitt M, Müller-Tidow C.
    Int J Cancer; 2022 Apr 01; 150(7):1141-1155. PubMed ID: 34766343
    [Abstract] [Full Text] [Related]

  • 8. The progress and current status of immunotherapy in acute myeloid leukemia.
    Yang D, Zhang X, Zhang X, Xu Y.
    Ann Hematol; 2017 Dec 01; 96(12):1965-1982. PubMed ID: 29080982
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
    Walter RB.
    Expert Opin Investig Drugs; 2018 Apr 01; 27(4):339-348. PubMed ID: 29534618
    [Abstract] [Full Text] [Related]

  • 14. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N.
    Adv Exp Med Biol; 2017 Apr 01; 995():73-95. PubMed ID: 28321813
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, Schmid C, Schweiger C, Tischer J, Kolb HJ, Schmetzer H.
    J Immunother; 2010 Jun 01; 33(5):523-37. PubMed ID: 20463595
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
    Acheampong DO, Adokoh CK, Asante DB, Asiamah EA, Barnie PA, Bonsu DOM, Kyei F.
    Biomed Pharmacother; 2018 Jan 01; 97():225-232. PubMed ID: 29091870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.